Cargando…

The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling

BACKGROUND: Patients suffering from chronic pain often also exhibit depression symptoms. Soluble epoxide hydrolase (sEH) inhibitors can decrease blood levels of inflammatory cytokines. However, whether inhibiting sEH signaling is beneficial for the comorbidity of pain and depression is unknown. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Ailin, Wu, Zifeng, Li, Shan, McReynolds, Cindy B., Wang, Di, Liu, Hanyu, Huang, Chaoli, He, Teng, Zhang, Xinying, Wang, Yuanyuan, Liu, Cunming, Hammock, Bruce D., Hashimoto, Kenji, Yang, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896784/
https://www.ncbi.nlm.nih.gov/pubmed/36732752
http://dx.doi.org/10.1186/s12967-023-03917-x
_version_ 1784882121410609152
author Luo, Ailin
Wu, Zifeng
Li, Shan
McReynolds, Cindy B.
Wang, Di
Liu, Hanyu
Huang, Chaoli
He, Teng
Zhang, Xinying
Wang, Yuanyuan
Liu, Cunming
Hammock, Bruce D.
Hashimoto, Kenji
Yang, Chun
author_facet Luo, Ailin
Wu, Zifeng
Li, Shan
McReynolds, Cindy B.
Wang, Di
Liu, Hanyu
Huang, Chaoli
He, Teng
Zhang, Xinying
Wang, Yuanyuan
Liu, Cunming
Hammock, Bruce D.
Hashimoto, Kenji
Yang, Chun
author_sort Luo, Ailin
collection PubMed
description BACKGROUND: Patients suffering from chronic pain often also exhibit depression symptoms. Soluble epoxide hydrolase (sEH) inhibitors can decrease blood levels of inflammatory cytokines. However, whether inhibiting sEH signaling is beneficial for the comorbidity of pain and depression is unknown. METHODS: According to a sucrose preference test (SPT), spared nerve injury (SNI) mice were classified into pain with or without an anhedonia phenotype. Then, sEH protein expression and inflammatory cytokines were assessed in selected tissues. Furthermore, we used sEH inhibitor TPPU to determine the role of sEH in chronic pain and depression. Importantly, agonists and antagonists of aryl hydrocarbon receptor (AHR) and translocator protein (TSPO) were used to explore the pathogenesis of sEH signaling. RESULTS: In anhedonia-susceptible mice, the tissue levels of sEH were significantly increased in the medial prefrontal cortex (mPFC), hippocampus, spinal cord, liver, kidney, and gut. Importantly, serum CYP1A1 and inflammatory cytokines, such as interleukin 1β (IL-1β) and the tumor necrosis factor α (TNF-α), were increased simultaneously. TPPU improved the scores of mechanical withdrawal threshold (MWT) and SPT, and decreased the levels of serum CYP1A1 and inflammatory cytokines. AHR antagonist relieved the anhedonia behaviors but not the algesia behaviors in anhedonia-susceptible mice, whereas an AHR agonist abolished the antidepressant-like effect of TPPU. In addition, a TSPO agonist exerted a similar therapeutic effect to that of TPPU, whereas pretreatment with a TSPO antagonist abolished the antidepressant-like and analgesic effects of TPPU. CONCLUSIONS: sEH underlies the mechanisms of the comorbidity of chronic pain and depression and that TPPU exerts a beneficial effect on anhedonia behaviors in a pain model via AHR and TSPO signaling. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03917-x.
format Online
Article
Text
id pubmed-9896784
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98967842023-02-04 The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling Luo, Ailin Wu, Zifeng Li, Shan McReynolds, Cindy B. Wang, Di Liu, Hanyu Huang, Chaoli He, Teng Zhang, Xinying Wang, Yuanyuan Liu, Cunming Hammock, Bruce D. Hashimoto, Kenji Yang, Chun J Transl Med Research BACKGROUND: Patients suffering from chronic pain often also exhibit depression symptoms. Soluble epoxide hydrolase (sEH) inhibitors can decrease blood levels of inflammatory cytokines. However, whether inhibiting sEH signaling is beneficial for the comorbidity of pain and depression is unknown. METHODS: According to a sucrose preference test (SPT), spared nerve injury (SNI) mice were classified into pain with or without an anhedonia phenotype. Then, sEH protein expression and inflammatory cytokines were assessed in selected tissues. Furthermore, we used sEH inhibitor TPPU to determine the role of sEH in chronic pain and depression. Importantly, agonists and antagonists of aryl hydrocarbon receptor (AHR) and translocator protein (TSPO) were used to explore the pathogenesis of sEH signaling. RESULTS: In anhedonia-susceptible mice, the tissue levels of sEH were significantly increased in the medial prefrontal cortex (mPFC), hippocampus, spinal cord, liver, kidney, and gut. Importantly, serum CYP1A1 and inflammatory cytokines, such as interleukin 1β (IL-1β) and the tumor necrosis factor α (TNF-α), were increased simultaneously. TPPU improved the scores of mechanical withdrawal threshold (MWT) and SPT, and decreased the levels of serum CYP1A1 and inflammatory cytokines. AHR antagonist relieved the anhedonia behaviors but not the algesia behaviors in anhedonia-susceptible mice, whereas an AHR agonist abolished the antidepressant-like effect of TPPU. In addition, a TSPO agonist exerted a similar therapeutic effect to that of TPPU, whereas pretreatment with a TSPO antagonist abolished the antidepressant-like and analgesic effects of TPPU. CONCLUSIONS: sEH underlies the mechanisms of the comorbidity of chronic pain and depression and that TPPU exerts a beneficial effect on anhedonia behaviors in a pain model via AHR and TSPO signaling. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03917-x. BioMed Central 2023-02-02 /pmc/articles/PMC9896784/ /pubmed/36732752 http://dx.doi.org/10.1186/s12967-023-03917-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Luo, Ailin
Wu, Zifeng
Li, Shan
McReynolds, Cindy B.
Wang, Di
Liu, Hanyu
Huang, Chaoli
He, Teng
Zhang, Xinying
Wang, Yuanyuan
Liu, Cunming
Hammock, Bruce D.
Hashimoto, Kenji
Yang, Chun
The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
title The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
title_full The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
title_fullStr The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
title_full_unstemmed The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
title_short The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
title_sort soluble epoxide hydrolase inhibitor tppu improves comorbidity of chronic pain and depression via the ahr and tspo signaling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896784/
https://www.ncbi.nlm.nih.gov/pubmed/36732752
http://dx.doi.org/10.1186/s12967-023-03917-x
work_keys_str_mv AT luoailin thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT wuzifeng thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT lishan thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT mcreynoldscindyb thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT wangdi thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT liuhanyu thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT huangchaoli thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT heteng thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT zhangxinying thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT wangyuanyuan thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT liucunming thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT hammockbruced thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT hashimotokenji thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT yangchun thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT luoailin solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT wuzifeng solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT lishan solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT mcreynoldscindyb solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT wangdi solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT liuhanyu solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT huangchaoli solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT heteng solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT zhangxinying solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT wangyuanyuan solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT liucunming solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT hammockbruced solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT hashimotokenji solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling
AT yangchun solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling